The estimated Net Worth of Jessica Hopfield is at least $15.7 Million dollars as of 13 May 2024. Jessica Hopfield owns over 45,000 units of Insulet stock worth over $15,417,321 and over the last 9 years he sold PODD stock worth over $0. In addition, he makes $241,611 as Independent Director at Insulet.
Jessica has made over 9 trades of the Insulet stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 45,000 units of PODD stock worth $253,800 on 13 May 2024.
The largest trade he's ever made was buying 80,000 units of Insulet stock on 10 March 2022 worth over $502,400. On average, Jessica trades about 6,362 units every 88 days since 2015. As of 13 May 2024 he still owns at least 67,700 units of Insulet stock.
You can see the complete history of Jessica Hopfield stock trades at the bottom of the page.
Dr. Jessica Hopfield Ph.D. serves as Independent Director of the Company. Dr. Hopfield has served on our Board of Directors since July 2015 and served as our Lead Independent Director from August 2016 through December 2018. In October 2015, Dr. Hopfield was appointed, and currently serves as, Chairperson of the Board of Trustees of the Joslin Diabetes Center. Since February 2018, Dr. Hopfield has served on the Board of Directors of Editas Medicine, Inc., a leading genome editing company developing genomic medicines to treat a broad class of diseases, and since January 2019, she has served on the Board of Directors of Radius Health, Inc., a biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. From 2013 to October 2015, Dr. Hopfield served as the Vice Chair of the Board of Trustees of the Joslin Diabetes Center. Dr. Hopfield is a distinguished healthcare executive and diabetes expert with over two decades of experience in the medical and healthcare fields. She is a strategic advisor and investor in start-up healthcare firms seeking to commercialize innovative intellectual property. From 1995 to 2009, Dr. Hopfield was a Partner at McKinsey & Company in their global pharmaceuticals and medical devices practice and she served clients across the pharmaceutical, biotech, medical device and consumer industries with a focus on strategy, R&D management and marketing. She also previously held management positions at Merck Sharp & Dohme Corp. in clinical development, outcomes research, and marketing. Dr. Hopfield earned a Bachelor of Science from Yale College, a Master of Business Administration from the Harvard Graduate School of Business Administration as a Baker Scholar, and a Doctor of Philosophy in Neuroscience/Biochemistry from The Rockefeller University.
As the Independent Director of Insulet, the total compensation of Jessica Hopfield at Insulet is $241,611. There are 16 executives at Insulet getting paid more, with Shacey Petrovic having the highest compensation of $5,883,980.
Jessica Hopfield is 55, he's been the Independent Director of Insulet since 2018. There are 10 older and 10 younger executives at Insulet. The oldest executive at Insulet Corporation is John Fallon, 72, who is the Independent Director.
Jessica's mailing address filed with the SEC is C/O EDITAS MEDICINE, INC.,, 11 HURLEY ST., CAMBRIDGE, MA, 02141.
Over the last 18 years, insiders at Insulet have traded over $64,849,299 worth of Insulet stock and bought 175,262 units worth $7,280,516 . The most active insiders traders include Jonathan Silverstein, Elizabeth H Weatherman, and Samuel D Colella. On average, Insulet executives and independent directors trade stock every 19 days with the average trade being worth of $2,473,148. The most recent stock trade was executed by Timothy J Scannell on 10 September 2024, trading 5,000 units of PODD stock currently worth $1,129,200.
insulet corporation is an innovative medical device company based in billerica, massachusetts. it was founded in 2000 with the mission of improving the lives of people with diabetes. specifically, through its revolutionary omnipod insulin management system, insulet seeks to expand the use of insulin pump therapy. studies have demonstrated the advantages of insulin pump therapy over multiple daily insulin injections (mdi); these advantages include better glycemic control, fewer hypoglycemic events, reduced glycemic variability1 and improved quality of life2. despite these benefits, most people still choose mdi therapy largely due to the complexity, cost and inconvenience of conventional pump technology. the omnipod is a discreet and easy-to-use system that eliminates many of the issues associated with conventional pumps. improvements include omnipod's lack of tubing; automated, virtually pain-free insertion; and two straightforward parts that communicate wirelessly. by breaking down
Insulet executives and other stock owners filed with the SEC include: